Treating Primary Node-Positive Prostate Cancer: A Scoping Review of Available Treatment Options
, Floris J. Pos 4, Jeroen A. van Moorselaar 3, Henk G. van der Poel 1,3, Wouter V. Vogel 4,5 and Pim J. van Leeuwen 1,*
Round 1
Reviewer 1 Report
- English language should be improved in bothgrammar and syntax- Lines 144-147 refer to ADT therapy in associationwith surgical therapy and radiotherapy, reaching the conclusion that the association of one or the otherdoes not give statistically significant differences. However, the age of the patients undergoing the treatments is not reported, therefore I suggest thatyou investigate this aspect further
- Paragraph 3.2.4 at line 231 discusses the use of docetaxel chemotherapy as an adjuvant, at thisregart i suggest the following article: https://pubmed.ncbi.nlm.nih.gov/32474391/
- It is possible to analyze the comorbidities of patientswith prostate cancer to understand whether they act as protective factors or risk factors for the progression of oncological disease in patients whoundergo ADT. At this regard the following articlecould be interesting: https://pubmed.ncbi.nlm.nih.gov/32570240/
Minor revisions
Author Response
Please see the attachment
Author Response File: 
Author Response.docx
Reviewer 2 Report
Nice review for patients with cN1/pN1 prostate cancer; Gives the reader an overview about potential treatment options. However, I missed a conclussion and recommendation which treatment would be best for the patient. Moreover, due to the introduction of new drugs like apalutamide, duralutamide in the course of treatment and modern diagnostic procederures like PSMA PET scan, a change and update in treatment options must be assumed in the near future.
Author Response
Please see the attachment
Author Response File: Author Response.docx
Round 2
Reviewer 1 Report
Authors answered all comments and suggestions.
Minor revisions.
Reviewer 2 Report
I am fine with the revised manuscript
